Infiltration of nanocarbon suspension into the tracheal cavity during surgical treatment of papillary thyroid carcinoma: a case report

Lin-bo Zhu¹, Feng Zhu², Peng-fei Li¹ and Peng-bin Zhang¹

Abstract
Cervical lymph node metastasis in patients with differentiated thyroid cancer affects postoperative recurrence and survival. Hypoparathyroidism is caused by parathyroid gland injury during thyroidectomy. Carbon nanoparticles can trace stained lymph nodes, aiding in thorough dissection of lymph nodes in the operation area. To reduce postoperative occurrence of hypoparathyroidism, the parathyroid glands and their functions (identified by negative imaging induced by carbon nanoparticles) are retained in situ. However, the safety and adverse effects of nanocarbon suspension in thyroid surgery have rarely been evaluated. In this report, we describe a patient with thyroid cancer who had carbon secretions in the trachea caused by nanocarbon suspension when tracheal intubation was performed under general anesthesia, and the inflatable balloon surface of the tracheal tube was covered with these secretions. The patient recovered without fever, cough, phlegm production, chest pain, hoarseness, or hypocalcemia-induced convulsions. No consensus has yet been reached on the most appropriate injection site, depth, dose, or waiting time for nanocarbons in thyroid cancer surgery. We believe that nanocarbon suspension is safe for use in thyroid cancer surgery, but the most appropriate injection depth should be based on the thickness of the thyroid gland tissue to avoid deep injection into the trachea.

¹Department of Thyroid and Breast Surgery, Beilun People’s Hospital, Ningbo, Zhejiang, China
²Thyroid Disease Diagnosis and Treatment Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Corresponding author:
Peng-fei Li, Department of Thyroid and Breast Surgery, Beilun People’s Hospital, No. 1288 Lushan East Road, Ningbo, Zhejiang 315800, China.
Email: nblyy1288@sina.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Papillary thyroid carcinoma, nanocarbon suspension, tracheal cavity, hypoparathyroidism, lymph node metastasis, case report

Date received: 14 October 2019; accepted: 4 March 2020

Introduction
Thyroid cancer is the most common malignant endocrine tumor. The incidence of papillary thyroid carcinoma (PTC) accounts for more than 85% of all thyroid cancers, and its incidence is increasing.1 Lymph node metastasis can occur in the early stages of PTC,2,3 and it has an impact on the prognosis and recurrence.4 Therefore, thyroidectomy combined with regional lymph node dissection for PTC has gained recognition.5 However, improvement in the detection rate of the suspected lymph nodes and a decrease in the incidence of postoperative hypoparathyroidism is challenging for thyroid surgeons.

Nanocarbons, through their identification and staining of lymph tissue, can improve the detection rate of lymph nodes and metastatic lymph nodes. The morphology and function of the parathyroid glands can be identified and retained in situ by negative parathyroid imaging, thus reducing the occurrence of hypoparathyroidism after the operation.4,5 However, a few adverse effects have been reported.6 In clinical practice, we encountered a patient with thyroid cancer who developed carbon secretions in the trachea caused by infiltration of nanocarbon suspension during the operation.

Case report
A 56-year-old man was admitted to the hospital 1 week after a left thyroid nodule was discovered during a physical examination. Color Doppler ultrasonography revealed a hypoechoic area approximately 1.2 × 0.8 cm in size in the central portion of the left thyroid gland. The area had unclear boundaries with the surrounding tissues, an irregular shape, aspect ratio imbalance, and fine sand calcification, and its TI-RADS grade was 4B. Fine needle aspiration cytology of the left thyroid nodule suggested papillary thyroid cancer. Preoperative thyroid function and serum calcium and phosphorus levels were within the normal range.

Surgical treatment was performed under general anesthesia on 14 June 2019. The patient was placed in the supine position and intubated under general anesthesia. The intubation process was smooth, and no abnormal secretions were found in the mouth, pharynx, or larynx. Shoulder pads were used to fully expose the neck. A low neck arc incision was made to separate the skin flaps and expose the thyroid glands. Using a 1-mL skin test syringe, nanocarbon suspension (H20041829; Chongqing LUMMY Pharmaceutical Co., Ltd., Congqing, China) was injected with a perpendicular orientation into the two upper and lower poles of the left thyroid gland to about 4 mm in depth. A total of 0.2 mL was slowly injected at each point, confirming the site before injection and avoiding injection into the blood vessels. The syringe was retrieved, and the injection point was pressed with gauze to prevent nanocarbon spillage from affecting the operation.

Left thyroid gland lobectomy and left central lymph node dissection were performed 10 minutes after injecting the nanocarbon suspension. The operation area was then rinsed with warm saline to check that the trachea was intact. No bubbles were
found in the operation area after checking with an artificial tympanic lung. No obvious diverticulum was found in the exposed trachea after the radical operation for left thyroid cancer, and no thyroglossal cyst or fistula was found after anterior laryngeal lymph node dissection. A drainage tube was placed in the operation area, and the incision was sutured layer by layer. The procedure was smooth. When the tracheal tube was retrieved, a large amount of carbon-containing secretions was found in the patient’s mouth, and the inflatable balloon surface of the tracheal tube was covered with these secretions (Figures 1 and 2 (a)). The secretions in the mouth were suctioned as much as possible with a sputum suction tube. The patient recovered smoothly and had no carbon-containing secretions after the operation. The drainage tube drained a small amount of reddish exudate and was removed on the second postoperative day. No fever, cough, sputum production, chest pain, hoarseness, or hypocalcemia-induced convulsions were noted after the operation. The serum calcium and parathormone levels were within the normal range. The patient was discharged on the third postoperative day. At the time of this writing, he was still undergoing follow-up without signs of discomfort.

**Discussion**

This report describes the case of a 56-year-old man with thyroid cancer who developed carbon secretions in the trachea caused by infiltration of nanocarbon suspension during the operation.

PTC accounts for more than 85% of all thyroid cancers, and lymph node metastasis can be present in 20% to 90% of patients with PTC at the time of the initial diagnosis. Cervical lymph node

![Figure 1](image1.jpg)

**Figure 1.** The inflatable balloon surface of the patient’s tracheal tube was covered with carbon secretion.

![Figure 2](image2.jpg)

**Figure 2.** (a) The inflatable balloon surface of the patient’s tracheal tube was covered with carbon secretion. (b) Normal tracheal intubation for comparison.
metastasis in patients with thyroid cancer is an important factor that affects recurrence and survival; thus, pathological thyroidec-
tomy combined with regional lymph node dissection is the main treatment of PTC. The incidence of permanent hypoparathy-
roidism after total thyroidectomy combined with central lymph node dissection ranges from 1.4% to 14.3%. The incidence of hypocalcemia caused by hypoparathyroidism can be as high as 9.9% to 20.8% and reduces the patient’s quality of life. Thus, it is particularly important to identify a method that can effectively remove lymph nodes and preserve the parathyroid glands.

As a new type of lymphatic tracer, carbon nanoparticles have been widely used in gastric cancer, colorectal cancer, and breast cancer surgeries and have achieved ideal results. In recent years, nanocarbon has been gradually applied in thyroid cancer surgery. Carbon nanoparticles are 150 nm in diameter, smaller than the lymphatic endothelial cell gap (500 nm) and larger than the capillary endothelial cell gap (30–50 nm). Therefore, carbon nanoparticles can enter lymphatic vessels and lymph nodes after being swallowed by macrophages, facilitating identification of lymph nodes by black staining; however, these particles do not enter the parathyroid glands because of the absence of a lymphatic connection between the thyroid and parathyroid glands, so the parathyroid gland remains unstained and thus protected. Studies have shown that the use of nanocarbon can detect lymph nodes, aiding in thorough dissection of the lymph nodes in the operative area and increasing the detection rate of lymph nodes and metastatic lymph nodes. Moreover, by negative imaging of the parathyroid glands, their morphology and function can be well recognized and preserved in situ, thus reducing the occurrence of hypoparathyroidism after the operation. In addition, the use of carbon nanoparticles can significantly reduce the incidence of parathyroid gland injury during the second operation for thyroid cancer.

Nanocarbons are reportedly safe for use in gastric cancer surgery. No allergies, toxic adverse effects, or safety concerns have been reported. To the best of our knowledge, there is no consensus on the most appropriate injection site, dosage, or waiting time of nanocarbons. Most clinicians inject the suspension in two to four points around the tumor, avoiding injection into the tumor. The total injection volume ranges from 0.2 to 0.5 mL (0.1 to 0.2 mL per point), with a waiting time of 10 to 20 minutes after injection for surgery. Although a few articles have mentioned the injection depth, this depth is not the same among different reports; some surgeons inject the suspension into the superficial thyroid gland to a depth of 2 to 3 mm, while others inject the suspension more deeply into the thyroid gland to no definite depth. In the present case, two injection points around the tumor were selected, the total injection volume was 0.4 mL, and the waiting time was 10 minutes; these parameters are consistent with those reported in the literature. When the tracheal tube was retrieved after the operation, some carbon-containing secretions were present in the mouth, and the inflatable balloon surface of the tracheal tube was covered with these secretions. This has three possible explanations. First, thyroid neoplasms are located in the middle pole, and nanocarbon is injected into the upper pole of the thyroid. The gland was thin in our patient; his preoperative color Doppler ultrasound images showed that the thickness of the upper and lower poles of the left thyroid gland was about 0.5 cm. Therefore, the syringe needle with an injection depth of 0.4 cm might have penetrated the gland and trachea or the tracheal mucosa, causing direct entry or infiltration of nanocarbon into the tracheal cavity.
through the mucosa. However, the trachea was carefully examined during the operation. No surgical wounds were found on the surface, and no air bubbles were found in the operation area as checked using an artificial tympanic lung. The drainage tube was well sealed after the operation. However, we could not exclude the possibility of a pinhole in the trachea because such a hole is very difficult to identify. Second, the interaction between the thyroid lymphatic vessels and lymphatic capillary networks of the tracheal mucosal layers may have contributed to a small amount of carbon nanoparticle leakage. Theoretically, an abnormal lymphatic structure (which was difficult to confirm in this patient) might be one cause of such a large amount of carbon nanoparticle leakage. Third, inadvertent injection into a possible tracheal diverticulum, thyroglossal cyst, or fistula can also cause carbon-containing secretions. However, our patient had no obvious tracheal diverticulum, thyroglossal cyst, or fistula on his preoperative neck computed tomography scan, which was consistent with the intraoperative exploration. Actually, a thyroglossal cyst is located in the anterior central region of the neck, so the possibility of injecting carbon nanoparticles into a thyroglossal cyst was very small in this patient with left thyroid cancer.

The manufacturer’s manual for the nanocarbon suspension indicated that adverse reactions are rare and include an occasional low-grade fever after the injection; however, our patient did not develop a fever after the operation. He recovered smoothly after the operation with no respiratory symptoms, such as fever, cough, sputum production, chest pain, hoarseness, hypocalcemia-induced convulsions, or other discomforts.

In conclusion, this case suggests that nanocarbon suspension is safe for use in thyroid cancer surgery. However, the most appropriate injection depth should be selected according to the thickness of the thyroid gland to avoid deep injection into the trachea.

Authors’ contributions
L-BZ drafted this manuscript. FZ and P-BZ was involved in acquisition of the data and preparation of the figures. P-FL conceived of the study and revised the manuscript. All authors read and approved the final manuscript.

Availability of data and materials
All data and materials are freely available upon request. For further information, please contact Dr. Peng-fei Li (nbblyy1288@sina.com), who is responsible for the dataset.

Consent for publication
Beilun District People’s Hospital obtained the patient’s consent for publication of his individual data.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Ethics approval and consent to participate
The Ethics Committee of Beilun District People’s Hospital approved this study. The analysis was performed in accordance with the ethical standards of the hospital and the tenets of the Declaration of Helsinki/Declaration of Istanbul. The patient described in this study provided written informed consent.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for profit sectors.

ORCID iD
Peng-fei Li https://orcid.org/0000-0001-7515-4408
References

1. Liu F, Zhu Y, Qian Y, et al. Recognition of sentinel lymph nodes in patients with papillary thyroid cancer by nano-carbon and methylene blue. Pak J Med Sci 2017; 33: 1485–1489.

2. Podnos YD, Smith D, Wagman LD, et al. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71: 731–734.

3. Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008; 144: 1070–1077.

4. Li Y, Jian WH, Guo ZM, et al. A meta-analysis of carbon nanoparticles for identifying lymph nodes and protecting parathyroid glands during surgery. Otolaryngol Head Neck Surg 2015; 152: 1007–1016.

5. Tian W, Jiang Y, Gao B, et al. Application of nano-carbon in lymph node dissection for thyroid cancer and protection of parathyroid glands. Med Sci Monit 2014; 20: 1925–1930.

6. Zhang X, Li JG, Zhang SZ, et al. Comparison of indocyanine green and carbon nanoparticles in endoscopic techniques for central lymph nodes dissection in patients with papillary thyroid cancer. Surg Endosc 2020. doi: 10.1007/s00464-019-07326-4 [Epub ahead of print]

7. White ML, Gauger PG and Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007; 31: 895–904.

8. Bergenfelz A, Jansson S, Kristoffersson A, et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg 2008; 393: 667–673.

9. Orosco RK, Lin HW and Bhattacharyya N. Ambulatory thyroidectomy: a multistate study of revisits and complications. Otolaryngol Head Neck Surg 2015; 152: 1017–1023.

10. Li Z, Ao S, Bu Z, et al. Clinical study of harvesting lymph nodes with carbon nanoparticles in advanced gastric cancer: a prospective randomized trial. World J Surg Oncol 2016; 14: 88.

11. Li K, Chen D, Chen W, et al. A case-control study of using carbon nanoparticles to trace decision-making lymph nodes around inferior mesenteric artery in rectal cancer. Surg Endosc 2019; 33: 904–910.

12. Wu X, Lin Q, Chen G, et al. Sentinel lymph node detection using carbon nanoparticles in patients with early breast cancer. PLoS One 2015; 10: e0135714.

13. Wang L, Yang D, Lv JY, et al. Application of carbon nanoparticles in lymph node dissection and parathyroid protection during thyroid cancer surgeries: a systematic review and meta-analysis. Onco Targets Ther 2017; 10: 1247–1260.

14. Chaojie Z, Shanshan L, Zhigong Z, et al. Evaluation of the clinical value of carbon nanoparticles as lymph node tracer in differentiated thyroid carcinoma requiring reoperation. Int J Clin Oncol 2016; 21: 68–74.

15. Zhang C, Li X, Zhang Z, et al. The potential role of carbon nanoparticles-assisted biopsy for sentinel lymph nodes of incidental thyroid carcinoma. Gland Surg 2019; 8: 370–377.

16. Yu W, Xu G, Sun J, et al. Carbon nanoparticles guide contralateral central neck dissection in patients with papillary thyroid cancer. Oncol Lett 2018; 16: 447–452.